Fish Oil ( DrugBank: Fish oil )

---

8 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	5
46	Malignant rheumatoid arthritis	5
49	Systemic lupus erythematosus	3
66	IgA nephropathy	1
96	Crohn disease	3
260	Sitosterolemia	1
294	Congenital diaphragmatic hernia	1
299	Cystic fibrosis	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003147-19-GR (EUCTR)	18/07/2016	25/05/2016	To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).	Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NEUROASPIS PLP10® INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS INN or Proposed INN: BORAGE OIL 20% GLA Other descriptive name: BORAGE OIL INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE INN or Proposed INN: Gamma-tocopherol	PALUPA Medical Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Greece
2	NCT02939079 (ClinicalTrials.gov)	April 2015	14/10/2016	Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients	Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-a , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Fingolimod;Dietary Supplement: Fish Oil;Drug: Placebo (for Fish Oil)	Isfahan University of Medical Sciences	Shiraz University of Medical Sciences	Completed	18 Years	45 Years	All	50	Phase 2/Phase 3	NULL
3	NCT01842191 (ClinicalTrials.gov)	May 2010	25/4/2013	Efficacy of Fish Oil in Multiple Sclerosis	Efficacy of Fish Oil on Serum TNFa, IL-1ß, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b	Relapsing- Remitting Multiple Sclerosis	Dietary Supplement: Fish Oil;Dietary Supplement: Placebo	Coordinación de Investigación en Salud, Mexico	NULL	Completed	18 Years	55 Years	Both	50	Phase 4	Mexico
4	NCT00676156 (ClinicalTrials.gov)	December 2005	7/5/2008	A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis	A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis	Multiple Sclerosis	Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	80 Years	Both	40	Phase 1	United States
5	NCT00122954 (ClinicalTrials.gov)	July 2005	20/7/2005	Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis	Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis	Multiple Sclerosis;Depression	Drug: Fish oil concentrate;Drug: Placebo	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	85 Years	All	39	Phase 1/Phase 2	United States

Back to top

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01274910 (ClinicalTrials.gov)	January 2011	4/1/2011	Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial	Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial	Rheumatoid Arthritis	Dietary Supplement: EPAX 6000 EE 1000mg (0.6 gr DHA+EPA);Dietary Supplement: Capsules (Placebo)	Rabin Medical Center	NULL	Recruiting	50 Years	80 Years	Both	60	N/A	Israel
2	NCT01351805 (ClinicalTrials.gov)	January 2011	4/5/2011	Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain	Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain	Autoimmune Diseases;Systemic Inflammatory Process;Knee Pain Chronic;Osteoarthritis;Rheumatoid Arthritis	Drug: Fish Oil;Dietary Supplement: Vitamin D;Other: placebo pill	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Active, not recruiting	50 Years	N/A	All	25876	N/A	United States
3	NCT01179971 (ClinicalTrials.gov)	December 2008	4/8/2010	n-3 and n-6 Fatty Acids in Rheumatoid Arthritis	Incorporation of n-3 Long Chain Polyunsaturated Fatty Acids and Gamma Linolenic Acid in Plasma Lipids, Cholesteryl Esters, and Erythrocyte Membranes and Their Influence on Disease Activity in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Fish oil, gamma-linolenic acid	Charite University, Berlin, Germany	University of Jena	Completed	18 Years	80 Years	Both	60	Phase 2	NULL
4	NCT00072982 (ClinicalTrials.gov)	November 2006	13/11/2003	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils	Rheumatoid Arthritis	Drug: fish oil;Drug: borage seed oil;Drug: combination fish oil and borage seed oil	National Center for Complementary and Integrative Health (NCCIH)	NULL	Active, not recruiting	18 Years	85 Years	Both	156	Phase 3	United States
5	NCT00094562 (ClinicalTrials.gov)	June 2004	20/10/2004	A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss	AAFA™ Fish Oil Nutritional Supplementation to Maintain Body Weight in Patients With Disease-Related Weight Loss	Cancer;Cancer Cachexia;Chronic Obstructive Pulmonary Disease;Chronic Heart Failure;Rheumatoid Arthritis	Drug: Fish oil supplement	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	90 Years	All	25	Phase 2	United States

Back to top

49. Systemic lupus erythematosus

---

Clinical trials : 993 /  Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02021513 (ClinicalTrials.gov)	January 2012	13/12/2013	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Dietary Supplement: Fish Oil;Dietary Supplement: Olive Oil	University of Texas Southwestern Medical Center	NULL	Completed	18 Years	64 Years	Both	50	Phase 2	United States
2	NCT00828178 (ClinicalTrials.gov)	February 2009	22/1/2009	Efficacy of Fish Oil in Lupus Patients	A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.	Systemic Lupus Erythematosus	Drug: Omega-3;Device: flow-mediated dilation of the brachial artery;Other: corn starch	Michelle Petri M.D.,MPH	NULL	Completed	18 Years	N/A	All	106	Phase 4	United States
3	EUCTR2004-004404-21-GB (EUCTR)	10/12/2004	17/02/2005	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Systemic Lupus Erythematosus	Trade Name: Omacor Product Name: Omacor INN or Proposed INN: Eicosapentaenoic acid INN or Proposed INN: Docosahexaenoic acid INN or Proposed INN: alpha-tocopherol	GreenPark Healthcare Trust	Queens University Belfast	Not Recruiting			Female: yes Male: yes	60	Phase 4	United Kingdom

66. IgA nephropathy

---

Clinical trials : 275 /  Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00498368 (ClinicalTrials.gov)	February 2009	9/7/2007	Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy	A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy	IgA Nephropathy	Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement	Mayo Clinic	Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen	Completed	18 Years	70 Years	All	34	Phase 4	United States

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02349594 (ClinicalTrials.gov)	January 2014	16/1/2015	Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease	Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study	Crohn Disease	Drug: Omegaven 10%;Drug: Intralipid 20%	Radboud University	NULL	Completed	18 Years	70 Years	Both	6	Phase 4	Netherlands
2	EUCTR2013-001212-30-NL (EUCTR)	04/07/2013	18/06/2013	Immune modulation by parenteral Fish oil in patients with Crohn’s disease	Modulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Omegaven Trade Name: Intralipid 10%		NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
3	ChiCTR-TRC-11001321	2011-05-01	2011-05-01	Effect of ?-3 Fish Oil Fat on Perioperative Immunity in Patients with Crohn's Disease	Effect of ?-3 Fish Oil Fat on Perioperative Immunity in Patients with Crohn's Disease	Crohn's disease;ICD:K50.9	control group:Total parenteral nutrition (TPN) will be administrated to patients from day1 to day7 after the operation. Non-protein energy of the TPN is 120kJ/kg/d, of which 60% is supplied by glucose and 40% by fat emulsion. Amino acid of the TPN is 0.8-1.0g/kg/d. Electrolyte, vitamins, trace elements will be added into the TPN. Glucose/insulin ratio is 5:1. In this group, medium-long chain triglyceride will be used.;?-3 Fat group:Total parenteral nutrition (TPN) will be administrated to patients from day1 to day7 after the operation. Non-protein energy of the TPN is 120kJ/kg/d, of which 60% is supplied by glucose and 40% by fat emulsion. Amino acid of the TPN is 0.8-1.0g/kg/d. Electrolyte, vitamins, trace elements will be added into the TPN. Glucose-insulin ratio is 5:1. In this group, medium-long chain triglyceride and ?-3 fish oil fat (Omegaven);	The First Affiliated Hospital of Sun Yat-sen University	NULL	Completed	14	75	Both	control group:30;?-3 Fat group:30;		China

260. Sitosterolemia

---

Clinical trials : 12 /  Drugs : 11 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathway : 1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01948648 (ClinicalTrials.gov)	February 6, 2018	6/9/2013	Effects of Fish Oil and Colesevelam (STAIR7007)	Effects of Fish Oil, Colesevelam and Combination Therapy on Sterol Metabolism in Sitosterolemia	Sitosterolemia	Drug: Colesevelam;Dietary Supplement: Fish Oil;Drug: Combination of fish oil and colesevelam	University of Manitoba	NULL	Active, not recruiting	8 Years	N/A	All	13	N/A	Canada

294. Congenital diaphragmatic hernia

---

Clinical trials : 16 /  Drugs : 26 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04031508 (ClinicalTrials.gov)	August 12, 2019	8/7/2019	Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH	Effect of a Parenteral Emulsion With LC-PUFA Omega 3 on Clinical Outcomes, Inflammatory and Oxidative Stress Markers in Neonates With Persistent Pulmonary Hypertension Associated With Congenital Diaphragmatic Hernia	Pulmonary Hypertension of Newborn;Diaphragm Defect	Combination Product: lipid injectable emulsion with Fish oil	Coordinación de Investigación en Salud, Mexico	University of Southampton;Universidad Nacional Autonoma de Mexico	Recruiting	1 Hour	15 Days	All	70	Phase 2	Mexico

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02646995 (ClinicalTrials.gov)	January 2016	22/12/2015	Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients		Cystic Fibrosis	Dietary Supplement: modified lipid formulation;Dietary Supplement: Fish oil	Nestlé	NULL	Completed	5 Years	18 Years	All	16	N/A	Switzerland

Back to top